We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

26 hedge funds and large institutions have $8.36M invested in Viridian Therapeutics in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.09% less ownership

Funds ownership: 1.35% → 1.27% (-0.09%)

7% less funds holding

Funds holding: 28 → 26 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

30% less capital invested

Capital invested by funds: $11.9M → $8.36M (-$3.59M)

Holders
26
Holders Change
-2
Holders Change %
-7.14%
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
6
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$305K
2
Citadel Advisors
Citadel Advisors
Florida
+$149K
3
VF
Virtu Financial
New York
+$111K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$86.5K
5
BCV
Banque Cantonale Vaudoise
Switzerland
+$49.7K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$477K
2
Squarepoint
Squarepoint
New York
-$132K
3
GPFA
Game Plan Financial Advisors
Ohio
-$77K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$71K
5
ARTA
A.R.T. Advisors
New York
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$3.01M – – –
AVA
2
Atlas Venture Advisors
Massachusetts
$2.45M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.23M -$2.58K -173 -0.2%
BlackRock
4
BlackRock
New York
$426K – – –
Qube Research & Technologies (QRT)
5
Qube Research & Technologies (QRT)
United Kingdom
$284K +$305K +20,447 +511%
JP Morgan Chase
6
JP Morgan Chase
New York
$255K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$204K +$86.5K +5,802 +49%
Citadel Advisors
8
Citadel Advisors
Florida
$128K +$149K +10,009 +1,002%
VF
9
Virtu Financial
New York
$87K +$111K +7,480 New
Renaissance Technologies
10
Renaissance Technologies
New York
$59K -$477K -32,007 -86%
Northern Trust
11
Northern Trust
Illinois
$56K +$17K +1,143 +31%
Goldman Sachs
12
Goldman Sachs
New York
$40K – – –
BCV
13
Banque Cantonale Vaudoise
Switzerland
$39K +$49.7K +3,333 New
Creative Planning
14
Creative Planning
Kansas
$18K +$3.98K +267 +21%
GCP
15
GSA Capital Partners
United Kingdom
$15K +$19.2K +1,288 New
ACP
16
Aveo Capital Partners
Colorado
$13K – – –
SAM
17
Seelaus Asset Management
New Jersey
$13K – – –
State Street
18
State Street
Massachusetts
$10K – – –
OIA
19
OneDigital Investment Advisors
Kansas
$9K +$11K +735 New
Wells Fargo
20
Wells Fargo
California
$7K +$8.59K +576 +3,388%
Bank Julius Baer & Co
21
Bank Julius Baer & Co
Switzerland
$1K – – –
Morgan Stanley
22
Morgan Stanley
New York
$1K – – –
VFA
23
Valeo Financial Advisors
Indiana
$1K +$1.8K +121 New
TRCT
24
Tower Research Capital (TRC)
New York
$1K +$2.35K +158 New
FCA
25
FinTrust Capital Advisors
South Carolina
$1 +$894 +60 New
1
2

VRDN Hedge Fund Activity: Q3 2020 in Review

26 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2020, worth a combined $8.36M — down 30% from $11.9M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of VRDN and 7 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 6 added.

The largest buyer was Qube Research & Technologies (QRT), adding an estimated $305K. The largest seller was Renaissance Technologies, cutting an estimated $477K.

  • 26 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2020, down from 28 in Q2 2020.
  • Funds reported $8.36M of Viridian Therapeutics stock for Q3 2020, down 30% quarter-over-quarter.
  • 7 funds opened new Viridian Therapeutics positions in Q3 2020 and 9 closed out, a net change of -2 holders.
  • The largest Viridian Therapeutics buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $305K added.
  • The largest Viridian Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $477K sold.

Based on aggregated 13F filings for Q3 2020.